Investors |

News

13 March 2019

LexaGene announces C$1.95 Million non-brokered private placement.

Read More

11 March 2019

LexaGene invited by the Food Safety and Inspection Service (FSIS), an agency of the USDA, to present a seminar on the benefits of adopting rapid genetic testing to improve food safety.

Read More

05 March 2019

05 March 2019 LexaGene announces that the LX technology successfully detected E. coli O157:H7 in a blinded study focused on romaine lettuce – a significant step in addressing the dire need for improved food safety testing. VIEW RELEASE

Read More

25 February 2019

LexaGene completes pilot clinical study and announces results. LexaGene analyzer technology successfully detects six out of six of known pathogens in the samples and is 97.5% concordant with reference laboratory generated data.

Read More

12 February 2019

LexaGene announces that its LX technology has successfully detected the presence of antibiotic resistance factors from pathogens that cause urinary tract infections (UTIs) in dogs in its ongoing clinical study.

Read More

07 February 2019

LexaGene announces that its LX technology has successfully detected the presence of two different pathogens from a single clinical urine sample in some of the first samples tested in the Company’s recently initiated clinical study.

Read More

04 February 2019

LexaGene announces that it has started a clinical study to collect data using its LX genetic analyzer technology. The study will include testing urine samples collected from dogs suspected of having a urinary tract infection (UTI).

Read More

22 January 2019

LexaGene announces it has formed a scientific advisory board comprised of key opinion leaders in the company’s targeted markets, namely food safety, veterinary diagnostics, and open-access markets such as biodefense.

Read More

03 January 2019

LexaGene was featured on ABC-affiliated television station WCVB Boston on a segment of ‘Cutting Edge’ on December 21, 2018.

Read More

10 December 2018

LexaGene announces completion of a syndromic panel to detect urinary tract infection (UTI) in small animals. The assay is capable of detecting each of the eight most common pathogens responsible for the majority of all clinical canine UTI cases.

Read More

03 December 2018

LexaGene recently had an Industry Engagement Meeting with the Department of Homeland Security (DHS) regarding the applications of the company’s technology for DHS’ program on Countering Weapons of Mass Destruction (CWMD).

Read More

28 November 2018

LexaGene named one of the 10 Most Promising Food and Beverages Solution Providers in 2018 by CIOReview.

Read More